228
Participants
Start Date
February 28, 2009
Primary Completion Date
April 30, 2011
Study Completion Date
July 31, 2011
HP802-247
One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
Placebo (Vehicle)
"Placebo (Vehicle) consisting of:~Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution"
St. Luke's Roosevelt Hospital Center, New York
Harrisburg Foot and Ankle Center, Harrisburg
Center for Advanced Wound Care, Reading
Johns Hopkins Wound Center, Baltimore
University of North Carolina, Chapel Hill
Doctors Research Network, South Miami
University of Miami, Miami
Robert J. Snyder, Tamarac
Rosalind Franklin University, North Chicago
Northwestern University Feinberg School of Medicine, Chicago
Passavant Area Hospital, Jacksonville
Southern Illinois University, Springfield
Wound Care Consultants, Dallas
Arlington Research Center, Arlington
Peripheral Vascular Associates, San Antonio
Southwest Regional Wound Care Center, Lubbock
Dixie Regional Medical Center's Wound Clinic, St. George
University of AZ College of Medicine, Tucson
Advanced Foot and Ankle Center, Las Vegas
Vascular Surgery Associates, Los Angeles
UCSD Wound Treatment and Research Center, San Diego
ILD Consulting, Inc., Encinitas
Center for Clinical Research, Castro Valley
Lake Washington Vascular, LLC, Bellevue
Providence Sacred Heart Medical Center Wound Clinic, Spokane
Boston Medical Center, Boston
New England Sinai Hospital, Stoughton
Vincent Giacalone, Emerson
Overlook Hospital Wound Healing Program, Summit
Aging Rehabilitation & Geriatric Care Research Center, London
Lead Sponsor
Healthpoint
INDUSTRY